Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis

Cecil Ross, MD, Savita Rangarajan, Mehran Karimi, MD, Bruce A. Schwartz, PhD, Sigurd Knaub, PhD, Flora Peyvandi, MD PhD

Blood (2015) 126 (23): 4680.

https://doi.org/10.1182/blood.V126.23.4680.4680

Published: 2015

Journal Articles

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Robert Klamroth, Toshko Lissitchkov, MD, Luminita Rusen, Olaf Walter, MD MBA, Johann Bichler, PhD, K John Pasi, Andreas Tiede, MD PhD, Sigurd Knaub, PhD

Blood (2015) 126 (23): 547.

https://doi.org/10.1182/blood.V126.23.547.547

Published: 2015

Journal Articles

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency

Bruce A. Schwartz, PhD, Savita Rangarajan, MBBS, FRCP, FRCPath, Flora Peyvandi, Mehran Karimi, MD, Sigurd Knaub, PhD

Blood (2014) 124 (21): 2817.

https://doi.org/10.1182/blood.V124.21.2817.2817

Published: 2014

Journal Articles

The PUP-GCP Clinical Trial: A Low Inhibitor Rate in Previously Untreated Patients with Severe Hemophilia a Treated with Octanate

Sigurd Knaub, PhD, Anna Klukowska, MD, Vladimir Komrska, Pawel Laguna, MD PhD, Vdovin Vladimir, MD, Martina Jansen

Blood (2014) 124 (21): 5051.

https://doi.org/10.1182/blood.V124.21.5051.5051

Published: 2014

Journal Articles

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Alok Srivastava, MD, Margit Serban, Prof. Dr., Sylvia Werner, Bruce A. Schwartz, PhD, Sigurd Knaub, PhD, Craig M. Kessler, MD

Blood (2014) 124 (21): 1504.

https://doi.org/10.1182/blood.V124.21.1504.1504

Published: 2014

Journal Articles

Efficacy, Immunogenicity, Pharmacokinetics, and Safety Of Human-cl rhFVIII – a GCP Study In Children With Severe Haemophilia A

Raina Liesner, Martina Jansen, Anna Klukowska, Vladimir Vdovin, MD, Tomasz Szczepanski, MD, PHD, Sigurd Knaub, PhD

Blood (2013) 122 (21): 3594.

https://doi.org/10.1182/blood.V122.21.3594.3594

Published: 2013

Journal Articles

Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A

Andreas Tiede, MD, PhD, Sigurd Knaub, PhD, Johannes Oldenburg, MD, Johann Bichler, PhD

Blood (2013) 122 (21): 3595.

https://doi.org/10.1182/blood.V122.21.3595.3595

Published: 2013

Journal Articles

Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate In Previously Untreated Patients With Severe Hemophilia A Treated With Octanate

Anna Klukowska, Martina Jansen, Vladimir Komrska, MD, Pawel Laguna, MD, PhD, Vladimir Vdovin, MD, Sigurd Knaub, PhD

Blood (2013) 122 (21): 3596.

https://doi.org/10.1182/blood.V122.21.3596.3596

Published: 2013

Journal Articles

Treatment of Congenital Fibrinogen Deficiency; Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate

Bruce A. Schwartz, PhD, Sigurd Knaub, PhD

Blood (2012) 120 (21): 4636.

https://doi.org/10.1182/blood.V120.21.4636.4636

Published: 2012

Journal Articles

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Sigurd Knaub, PhD, Toshko Lissitchkov, MD, PhD, Kingsley Hampton, Mario Von Depka, Savita Rangarajan, MBBS, FRCP, FRCPath, Charles R.M. Hay, MD, FRCP, FRCPath, Edward GD Tuddenham, MBBS, FRCP, FRCPath, PhD, Peter Collins, MD, Katharina Holstein, MD, Angela Huth-Kühne, Ingrid Pabinger, MD, Johannes Oldenburg, MD, Johann Bichler

Blood (2012) 120 (21): 1132.

https://doi.org/10.1182/blood.V120.21.1132.1132

Published: 2012

Journal Articles

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate ® in Children Under 6 Years of Age with Inherited Von Willebrand Disease,

Ulrike Nowak-Gottl, MD, Alexandra Russo, MD, Anne Kruempel, MD, Martina Jansen, Sigurd Knaub, PhD

Blood (2011) 118 (21): 3330.

https://doi.org/10.1182/blood.V118.21.3330.3330

Published: 2011

Journal Articles

A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,

Sigurd Knaub, PhD, Andreas Tiede, MD, PhD, Toshko Lissitchkov, MD, PhD, Leonard A. Valentino, MD, FAAP, Jerry Sherman Powell, MD, Marilyn J. Manco-Johnson, MD

Blood (2011) 118 (21): 3309.

https://doi.org/10.1182/blood.V118.21.3309.3309

Published: 2011

Journal Articles

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Craig M. Kessler, MD, Bruce A. Schwartz, PhD, Oliver Hegener, Olaf Walter, MD, Sigurd Knaub, PhD

Blood (2010) 116 (21): 1424.

https://doi.org/10.1182/blood.V116.21.1424.1424

Published: 2010

Journal Articles

The Clinical Development of the First Recombinant FVIII From a Human Cell Line.

Sigurd Knaub, PhD, Nadezhda Zozulya, MD, PhD

Blood (2009) 114 (22): 4439.

https://doi.org/10.1182/blood.V114.22.4439.4439

Published: 2009

Journal Articles

Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency.

Marilyn J. Manco-Johnson, MD, Giancarlo Castaman, MD, Sandra Fremann, MD, Sigurd Knaub, PhD, Gavino Piseddu, MD, Pier M. Mannucci, MD

Blood (2008) 112 (11): 2268.

https://doi.org/10.1182/blood.V112.11.2268.2268

Published: 2008

Journal Articles

Pharmacokinetic Analysis of a von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate in Adults and Children with von Willebrand Disease (VWD).

Jorge Di Paola, MD, Stephan Lethagen, MD, PhD, Joan Gill, MD, Pier Mannucci, MD, Jonathan Bernstein, MD, William Nichols, MD, Carl Friedman, MD, Sigurd Knaub, PhD, Garrett Bergman, MD

Blood (2007) 110 (11): 2140.

https://doi.org/10.1182/blood.V110.11.2140.2140

Published: 2007

Journal Articles

von Willebrand Factor/Factor VIII Concentrate (Humate-P®) Is Safe and Effective in the Prevention of Perioperative Bleeding in Patients with Very Low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo).

Joan Cox Gill, MD, Cindy A. Leissinger, MD, Jorge DiPaola, MD, Jonathan Bernstein, MD, Margaret V. Ragni, MD, Rinah Shopnick, MD, Leonard A. Valentino, MD, Sigurd Knaub, PhD, Carl Friedman, MD

Blood (2006) 108 (11): 4071.

https://doi.org/10.1182/blood.V108.11.4071.4071

Published: 2006

Journal Articles

Pharmacokinetics of C1 Esterase Inhibitor, Human (Pasteurized) in Subjects with Hereditary Angioedema.

Wolfhart Kreuz, MD, Inmarculada Martinez-Saguer, MD, Hildegard Stoll, MD, Sigurd Knaub, PhD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 1031.

https://doi.org/10.1182/blood.V104.11.1031.1031

Published: 2004

NARROW

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis

Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency

The PUP-GCP Clinical Trial: A Low Inhibitor Rate in Previously Untreated Patients with Severe Hemophilia a Treated with Octanate

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Efficacy, Immunogenicity, Pharmacokinetics, and Safety Of Human-cl rhFVIII – a GCP Study In Children With Severe Haemophilia A

Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A

Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate In Previously Untreated Patients With Severe Hemophilia A Treated With Octanate

Treatment of Congenital Fibrinogen Deficiency; Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate

Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A

Results of a Prospective, Open-Label Trial to Assess the Efficacy, Safety and Immunogenicity of Wilate ® in Children Under 6 Years of Age with Inherited Von Willebrand Disease,

A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

The Clinical Development of the First Recombinant FVIII From a Human Cell Line.

Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency.

Pharmacokinetic Analysis of a von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate in Adults and Children with von Willebrand Disease (VWD).

von Willebrand Factor/Factor VIII Concentrate (Humate-P®) Is Safe and Effective in the Prevention of Perioperative Bleeding in Patients with Very Low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo).

Pharmacokinetics of C1 Esterase Inhibitor, Human (Pasteurized) in Subjects with Hereditary Angioedema.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only